A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

► First study of the final formulation of a bivalent rLP2086 vaccine in young adults. ► The vaccine was well tolerated; most AEs were not unusual for a vaccine trial. ► Most participants achieved hSBA titres ≥ 1:4 against a panel of MnB target strains. ► hSBA MnB strains expressed diverse fHBP variants and suggest broad vaccine coverage. ► Data support further clinical development of the bivalent rLP2086 vaccine.